Novo Nordisk's Buyback Billions Mask a Race It's Increasingly Running From Behind
Published on 09/01/2026 at 13:42 | Editorial boerse-global.de
There is a particular kind of corporate tell that emerges when a company starts buying back its own shares with unusual urgency. It can signal confidence, or it can signal a management team trying to hold the line while the story around the stock does the opposite. For Novo Nordisk, the recent numbers suggest the latter has taken hold.
The Danish drugmaker disclosed in late August that it had repurchased over 30.9 million B-shares at an average price of 281.08 Danish kroner, spending roughly 8.7 billion kroner. That drawdown comes from a 15 billion kroner buyback program launched in early February — a program that, on its face, projects strength. But the market is increasingly reading it as a defensive maneuver, a way to keep the share price steady while the narrative around the company's once-unassailable GLP-1 franchise erodes.
A First-Mover Advantage That's Already Fading
The most telling development may be happening in the oral weight-loss arena, where Novo's early lead is slipping away. Eli Lilly introduced its oral obesity treatment Foundayo in the UK in mid-August, following regulatory approval on August 10. Reuters characterized the move as a direct competitive strike at Novo's oral Wegovy pill, which had previously held the distinction of being the first oral GLP-1 product on the British market.
Novo has effectively surrendered its first-mover advantage on a market it helped define. That loss of momentum is arguably more consequential than any single analyst downgrade, yet it has received comparatively little attention in the broader conversation about the stock.
The competitive pressure isn't only coming from above. Polish drugmaker Celon Pharma reported that its experimental semaglutide product, Reduzek, achieved bioequivalence with Wegovy and Ozempic in an early-stage study. The candidate is being developed as a generic alternative, and while the data is preliminary, the implication is significant: if a copycat product can already match the originals, the economic value of Novo's patent protection may erode faster than the market currently prices in.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
Quality Concerns and a Slower Pipeline
There's also a self-inflicted wound to consider. Scholar Rock was forced to withdraw its European filing for a spinal muscular atrophy treatment after problems surfaced at a manufacturing facility owned by Novo Nordisk. Quality issues in a company's own supply chain are not a side note — they cut to the core of the trust that regulators and partners place in a manufacturer.
On the positive side of the ledger, Novo launched the late-stage OASIS-5 study on August 12, testing lower maintenance doses of the Wegovy pill over 60 weeks, with results expected by 2028. It's a sensible effort to differentiate the product, but it also underscores just how long investors will need to wait. The same patience is required for the microbiome research being pursued with Novonesis, which isn't expected to deliver results until the second half of 2027. The growth story, in other words, is tethered to timelines that stretch well beyond the current market cycle.
The Numbers Are Fine — The Trust Isn't
The operational picture, taken on its own, is hardly a disaster. Second-quarter revenue rose 7 percent at constant exchange rates to 78.488 billion kroner, while operating profit climbed 11 percent. Management raised its full-year guidance, now expecting a decline of between zero and 6 percent at constant exchange rates, an improvement from the prior range of minus 12 to minus 4 percent. Adjusted earnings per share of $0.96 came in well ahead of the consensus estimate of $0.81.
Yet the market's response was muted. Investors are looking past the current quarter to a more uncomfortable question: how durable is the pipeline over the next several years? That's the concern Deutsche Bank addressed when it cut its rating to "Sell" and trimmed its price target by 9 percent, citing slower growth expected for 2027, pipeline setbacks — including the failed cardiovascular endpoint for Ziltivekimab — and the longer-term threat of patent expirations. The bank's analyst pointed to "mixed" quarterly results, with investors fixating on a modest sales miss for the Wegovy pill and the disappointing trial outcome for CagriSema.
JPMorgan, by contrast, raised its price target in late August, arguing that generic erosion for Ozempic has been less severe than expected and that more favorable gross price adjustments in the US provide additional support. Two major banks, same data, opposite conclusions. That kind of divergence rarely signals a clear or compelling investment story.
A Market Still Skeptical
The stock trades near its 100-day moving average of €39.47, roughly 29 percent above its 52-week low of €30.25. But the technical picture tells a more cautious story: the RSI sits at 41.4, and the share price remains 6.7 percent below its 50-day average. The recovery, such as it is, hasn't convinced the market.
The next test comes on September 21, when Novo hosts its capital markets day in London. Management is expected to lay out strategy, pipeline details, and operational outlook in depth. It's a moment that will reveal whether the company can win back skeptics with a persuasive narrative — or whether the buyback program remains the primary support keeping the share price from more meaningful downside.
The fundamental question lingers: when a company pours billions into its own stock, is it demonstrating conviction, or is it acknowledging that it lacks more convincing arguments? For Novo Nordisk, the answer increasingly looks like the latter. The operational stabilization is real, but so is the strategic gap opening up with competitors — and that gap may prove far more consequential.
Ad
Novo Nordisk Stock: New Analysis - 1 September
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
